The American Journal of Managed Care

Flotufolastat F 18 Injection for Prostate Cancer Added to NCCN Guidelines

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...
Business Wire

Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 LIGHTHOUSE Trial of POSLUMA® (Flotufolastat F 18) Injection in Newly Diagnosed Prostate Cancer

− Oral presentation highlighted at 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting – MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a ...
ascopubs.org

GLIPR1/RTVP-1 tumor suppressor gene expressed by adenovirus vector as neoadjuvant intraprostatic injection for localized high-risk prostate cancer preceding prostatectomy.

A detailed analysis of von Hippel Lindau (VHL) mutations in sporadic clear cell renal carcinoma (ccRCC), VHL syndrome, and Chuvash polycythaemia. Background: GLIPR1/RTVP-1 is up-regulated by p53 in ...
News Medical

Estradiol patches as effective as injections for locally advanced prostate cancer

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...